세계의 로타바이러스 예방 시장 보고서(2025년)

Rotavirus prophylaxis involves the prevention of rotavirus infection through vaccination, aiming to shield infants and young children from this highly contagious illness that triggers inflammation in the stomach and bowels. The primary objective is to provide protection against the infection's severity.

The primary methods employed for rotavirus prophylaxis include the administration of vaccines such as Rotarix, Rotavac, Rotavin-M1, as well as the utilization of oral rehydration fluids, among other interventions. Rotavirus, a viral agent, is responsible for inducing severe stomach and intestinal disorders, often characterized by symptoms like fever, vomiting, and diarrhea. These interventions are deployed through various routes of administration, including oral and parenteral methods, and are readily accessible through outlets such as hospital pharmacies, retail pharmacies, online pharmacy platforms, and others. The intended beneficiaries of these preventive measures encompass hospitals, specialty clinics, home care services, and various other healthcare settings.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The rotavirus prophylaxis market research report is one of a series of new reports from The Business Research Company that provides rotavirus prophylaxis market statistics, including rotavirus prophylaxis industry global market size, regional shares, competitors with a rotavirus prophylaxis market share, detailed rotavirus prophylaxis market segments, market trends and opportunities and any further data you may need to thrive in the rotavirus prophylaxis industry. This rotavirus prophylaxis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The rotavirus prophylaxis market size has grown strongly in recent years. It will grow from $9.05 billion in 2024 to $9.94 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to vaccine access and equity, emerging rotavirus strains, r&d investments, public health preparedness.

The rotavirus prophylaxis market size is expected to see strong growth in the next few years. It will grow to $14.45 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to gastrointestinal disease burden, global expansion, vaccination programs, vaccine confidence. Major trends in the forecast period include next-generation vaccines, combination vaccines, vaccine delivery innovation, global immunization collaboration.

The forecast of 9.8% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. immunization efforts by increasing costs for rotavirus vaccines imported from Belgium and India, potentially reducing pediatric vaccination rates and raising public health expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growth of the rotavirus prophylaxis market is anticipated to be powered by the rising number of vaccine courses. A vaccine course, which consists of specific doses of a vaccine designed to confer protection against a particular disease, plays a pivotal role in the battle against rotavirus infection. The vaccine course dosage acts as a catalyst for the immunological response, significantly enhancing immunity against rotavirus and reducing the risk of illness. This leads to an overall increase in vaccine efficacy. As an illustration, a report by the United Nations International Children's Emergency Fund (UNICEF) published in January 2022 revealed that approximately 5.71 million courses of RV1-5 frozen rotavirus vaccine were manufactured in 2022, with a projected surge to 9.31 million courses by 2028. Furthermore, 5.29 million courses of RV5-2 lyophilized rotavirus vaccines were produced in 2022, with an expected rise to 6.13 million courses by 2028. Consequently, the growing availability of vaccines will be a driving force behind the rotavirus prophylaxis market.

The rotavirus prophylaxis market is expected to experience significant growth fueled by institutional funding. Institutional funding entails the allocation of financial, human, or material resources to support various programs, needs, or projects. The escalating incidence of rotavirus cases has attracted funding from government bodies and private organizations. This financial support encompasses both monetary and technical assistance, spanning different stages of rotavirus vaccine and oral medication development. To exemplify, in April 2022, Indiana University, a public research university based in the United States, secured a $1.2 million grant from the venture capital firm GIVAX Inc. The grant aims to facilitate the development of innovative technology for a combined oral rotavirus-norovirus vaccine for infants. This groundbreaking technology expands the scope of the existing rotavirus vaccine to include protection against norovirus, a highly contagious virus responsible for severe vomiting and diarrhea in young children. Therefore, the increased availability of funding sources is poised to propel the rotavirus prophylaxis market.

Prominent companies operating in the rotavirus prophylaxis market are actively engaged in vaccine development to meet the evolving demands of consumers. The process of vaccine approvals involves a rigorous and multi-stage development and testing procedure. These approvals are essential in ensuring the safety and effectiveness of vaccines for preventing this viral disease, especially in infants and young children. For instance, in November 2022, GlaxoSmithKline PLC, a U.K.-based pharmaceutical and biotechnology company, announced the approval by the Food and Drug Administration (FDA) of an oral-dosing applicator-only presentation (liquid formulation) of ROTARIX (Rotavirus Vaccine, Live and Oral). This vaccine prevents rotavirus gastroenteritis in infants, caused by G1 and non-G1 types (G3, G4, and G9). The novel oral-dosing applicator-only presentation is entirely liquid and should not be reconstituted before use. Both ROTARIX lyophilized and liquid formulations are administered orally in a two-dose series, containing the same live, human-attenuated rotavirus strain and manufactured using similar methods.

In August 2022, Aspen Pharmacare Holdings Limited (APN), a South Africa-based pharmaceutical company, entered into a strategic collaboration with Serum Institute of India Pvt. Ltd. The partnership with the Serum Institute of India (SII) aimed to manufacture and distribute four Aspen-branded vaccines in Africa. This collaboration sought to bolster Africa's health manufacturing capacity and provide affordable vaccine access to the African population. Serum Institute of India Pvt. Ltd. is a vaccine manufacturer based in India, including vaccines for rotavirus.

Major companies operating in the rotavirus prophylaxis market are Pfizer Inc., Johnson & Johnson, Merck & Co., Novartis AG, Sanofi SA, Astra Zeneca Pharmaceuticals LP, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Sinovac Biotech Ltd., Astellas Pharma Inc., CSL Limited, Bharat Biotech International Limited, Daiichi Sankyo Co. Ltd., Lupin Limited, Mitsubishi Tanabe Pharma Corporation, Serum Institute of India Pvt. Ltd., Zydus Lifescience Ltd., Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Biocad Biopharmaceutical Co., Bharat Serums and Vaccines Limited, Biological E Limited, PT Bio Farma, Panacea Biotec Ltd., Shanghai Institute of Biological Products (SIBP).

North America was the largest region in the rotavirus prophylaxis market in 2024. The regions covered in rotavirus prophylaxis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the rotavirus prophylaxis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The rotavirus prophylaxis market consists of revenues earned by entities by providing services such as vaccination, clinical management, awareness programs and diagnosis. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Rotavirus Prophylaxis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on rotavirus prophylaxis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for rotavirus prophylaxis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The rotavirus prophylaxis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Rotarix; Rotavac; Rotavin-M1; Oral Rehydration Fluid; Other Treatments
• 2) By Route of Administration: Oral; Parenteral; Other Route of Administrations
• 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
• 4) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users
• Subsegments:
• 1) By Rotarix: Single Dose; Multi-Dose
• 2) By Rotavac: Liquid Formulation; Freeze-Dried Formulation
• 3) By Rotavin-M1: Liquid Formulation; Freeze-Dried Formulation
• 4) By Oral Rehydration Fluid: Electrolyte Solutions; Glucose-Based Solutions
• 5) By Other Treatments: Supportive Care; Antidiarrheal Medications
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co.; Novartis AG; Sanofi SA; Astra Zeneca Pharmaceuticals LP; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Sinovac Biotech Ltd.; Astellas Pharma Inc.; CSL Limited; Bharat Biotech International Limited; Daiichi Sankyo Co. Ltd.; Lupin Limited; Mitsubishi Tanabe Pharma Corporation; Serum Institute of India Pvt. Ltd.; Zydus Lifescience Ltd.; Emergent BioSolutions Inc.; Hualan Biological Engineering Inc.; Biocad Biopharmaceutical Co.; Bharat Serums and Vaccines Limited; Biological E Limited; PT Bio Farma; Panacea Biotec Ltd.; Shanghai Institute of Biological Products (SIBP)
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Rotavirus Prophylaxis Market Characteristics

3. Rotavirus Prophylaxis Market Trends And Strategies

4. Rotavirus Prophylaxis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Rotavirus Prophylaxis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Rotavirus Prophylaxis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Rotavirus Prophylaxis Market Growth Rate Analysis
• 5.4. Global Rotavirus Prophylaxis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Rotavirus Prophylaxis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Rotavirus Prophylaxis Total Addressable Market (TAM)

6. Rotavirus Prophylaxis Market Segmentation

• 6.1. Global Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rotarix
• Rotavac
• Rotavin-M1
• Oral Rehydration Fluid
• Other Treatments
• 6.2. Global Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Route of Administrations
• 6.3. Global Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Other Distribution Channels
• 6.4. Global Rotavirus Prophylaxis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End-Users
• 6.5. Global Rotavirus Prophylaxis Market, Sub-Segmentation Of Rotarix, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single Dose
• Multi-Dose
• 6.6. Global Rotavirus Prophylaxis Market, Sub-Segmentation Of Rotavac, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Liquid Formulation
• Freeze-Dried Formulation
• 6.7. Global Rotavirus Prophylaxis Market, Sub-Segmentation Of Rotavin-M1, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Liquid Formulation
• Freeze-Dried Formulation
• 6.8. Global Rotavirus Prophylaxis Market, Sub-Segmentation Of Oral Rehydration Fluid, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Electrolyte Solutions
• Glucose-Based Solutions
• 6.9. Global Rotavirus Prophylaxis Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Supportive Care
• Antidiarrheal Medications

7. Rotavirus Prophylaxis Market Regional And Country Analysis

• 7.1. Global Rotavirus Prophylaxis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Rotavirus Prophylaxis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Rotavirus Prophylaxis Market

• 8.1. Asia-Pacific Rotavirus Prophylaxis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Rotavirus Prophylaxis Market

• 9.1. China Rotavirus Prophylaxis Market Overview
• 9.2. China Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Rotavirus Prophylaxis Market

• 10.1. India Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Rotavirus Prophylaxis Market

• 11.1. Japan Rotavirus Prophylaxis Market Overview
• 11.2. Japan Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Rotavirus Prophylaxis Market

• 12.1. Australia Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Rotavirus Prophylaxis Market

• 13.1. Indonesia Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Rotavirus Prophylaxis Market

• 14.1. South Korea Rotavirus Prophylaxis Market Overview
• 14.2. South Korea Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Rotavirus Prophylaxis Market

• 15.1. Western Europe Rotavirus Prophylaxis Market Overview
• 15.2. Western Europe Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Rotavirus Prophylaxis Market

• 16.1. UK Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Rotavirus Prophylaxis Market

• 17.1. Germany Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Rotavirus Prophylaxis Market

• 18.1. France Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Rotavirus Prophylaxis Market

• 19.1. Italy Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Rotavirus Prophylaxis Market

• 20.1. Spain Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Rotavirus Prophylaxis Market

• 21.1. Eastern Europe Rotavirus Prophylaxis Market Overview
• 21.2. Eastern Europe Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Rotavirus Prophylaxis Market

• 22.1. Russia Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Rotavirus Prophylaxis Market

• 23.1. North America Rotavirus Prophylaxis Market Overview
• 23.2. North America Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Rotavirus Prophylaxis Market

• 24.1. USA Rotavirus Prophylaxis Market Overview
• 24.2. USA Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Rotavirus Prophylaxis Market

• 25.1. Canada Rotavirus Prophylaxis Market Overview
• 25.2. Canada Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Rotavirus Prophylaxis Market

• 26.1. South America Rotavirus Prophylaxis Market Overview
• 26.2. South America Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Rotavirus Prophylaxis Market

• 27.1. Brazil Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Rotavirus Prophylaxis Market

• 28.1. Middle East Rotavirus Prophylaxis Market Overview
• 28.2. Middle East Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Rotavirus Prophylaxis Market

• 29.1. Africa Rotavirus Prophylaxis Market Overview
• 29.2. Africa Rotavirus Prophylaxis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Rotavirus Prophylaxis Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Rotavirus Prophylaxis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Rotavirus Prophylaxis Market Competitive Landscape And Company Profiles

• 30.1. Rotavirus Prophylaxis Market Competitive Landscape
• 30.2. Rotavirus Prophylaxis Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

31. Rotavirus Prophylaxis Market Other Major And Innovative Companies

• 31.1. Astra Zeneca Pharmaceuticals LP
• 31.2. GlaxoSmithKline plc
• 31.3. Takeda Pharmaceutical Company Limited
• 31.4. Sinovac Biotech Ltd.
• 31.5. Astellas Pharma Inc.
• 31.6. CSL Limited
• 31.7. Bharat Biotech International Limited
• 31.8. Daiichi Sankyo Co. Ltd.
• 31.9. Lupin Limited
• 31.10. Mitsubishi Tanabe Pharma Corporation
• 31.11. Serum Institute of India Pvt. Ltd.
• 31.12. Zydus Lifescience Ltd.
• 31.13. Emergent BioSolutions Inc.
• 31.14. Hualan Biological Engineering Inc.
• 31.15. Biocad Biopharmaceutical Co.

32. Global Rotavirus Prophylaxis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Rotavirus Prophylaxis Market

34. Recent Developments In The Rotavirus Prophylaxis Market

35. Rotavirus Prophylaxis Market High Potential Countries, Segments and Strategies

• 35.1 Rotavirus Prophylaxis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Rotavirus Prophylaxis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Rotavirus Prophylaxis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer